Hematological improvement during iron-chelation therapy in myelodysplastic syndromes: The experience of the "Rete Ematologica Lombarda"

Alfredo Molteni, Marta Riva, Annamaria Pellizzari, Lorenza Borin, Alessandra Freyre, Rosa Greco, Marta Ubezio, Massimo Bernardi, Alessio Fariciotti, Guido Nador, Michele Nichelatti, Emanuele Ravano, Enrica Morra

Research output: Contribution to journalArticle

Abstract

To analyze the unpredicted event of hematological improvement (HI) during iron-chelation therapy (ICT), we reviewed a series of 53 myelodysplastic patients with transfusion dependency in a retrospective study involving 8 centers afferent to the "Rete Ematologica Lombarda". According to the IWG response criteria published in the year 2000, we observed erythroid responses in 19 patients (35.1%), 5 major (9.2%) and 14 minor (25.9%). In the assessable patients, platelet response was 8/13 (61%) and neutrophil response was 13/17 (76.4%). Only in patients with erythroid improvement, multilineage responses were observed. Apparently, patients with greater erythropoiesis dysfunction may take more advantage.

Original languageEnglish
Pages (from-to)1233-1240
Number of pages8
JournalLeukemia Research
Volume37
Issue number10
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Chelation Therapy
Myelodysplastic Syndromes
Iron
Erythropoiesis
Neutrophils
Blood Platelets
Retrospective Studies

Keywords

  • Hematological improvement
  • Iron-chelation therapy
  • Myelodysplastic syndromes

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Hematological improvement during iron-chelation therapy in myelodysplastic syndromes : The experience of the "Rete Ematologica Lombarda". / Molteni, Alfredo; Riva, Marta; Pellizzari, Annamaria; Borin, Lorenza; Freyre, Alessandra; Greco, Rosa; Ubezio, Marta; Bernardi, Massimo; Fariciotti, Alessio; Nador, Guido; Nichelatti, Michele; Ravano, Emanuele; Morra, Enrica.

In: Leukemia Research, Vol. 37, No. 10, 10.2013, p. 1233-1240.

Research output: Contribution to journalArticle

Molteni, A, Riva, M, Pellizzari, A, Borin, L, Freyre, A, Greco, R, Ubezio, M, Bernardi, M, Fariciotti, A, Nador, G, Nichelatti, M, Ravano, E & Morra, E 2013, 'Hematological improvement during iron-chelation therapy in myelodysplastic syndromes: The experience of the "Rete Ematologica Lombarda"', Leukemia Research, vol. 37, no. 10, pp. 1233-1240. https://doi.org/10.1016/j.leukres.2013.07.006
Molteni, Alfredo ; Riva, Marta ; Pellizzari, Annamaria ; Borin, Lorenza ; Freyre, Alessandra ; Greco, Rosa ; Ubezio, Marta ; Bernardi, Massimo ; Fariciotti, Alessio ; Nador, Guido ; Nichelatti, Michele ; Ravano, Emanuele ; Morra, Enrica. / Hematological improvement during iron-chelation therapy in myelodysplastic syndromes : The experience of the "Rete Ematologica Lombarda". In: Leukemia Research. 2013 ; Vol. 37, No. 10. pp. 1233-1240.
@article{8c102ec44ba84868a87271c493e0f1b0,
title = "Hematological improvement during iron-chelation therapy in myelodysplastic syndromes: The experience of the {"}Rete Ematologica Lombarda{"}",
abstract = "To analyze the unpredicted event of hematological improvement (HI) during iron-chelation therapy (ICT), we reviewed a series of 53 myelodysplastic patients with transfusion dependency in a retrospective study involving 8 centers afferent to the {"}Rete Ematologica Lombarda{"}. According to the IWG response criteria published in the year 2000, we observed erythroid responses in 19 patients (35.1{\%}), 5 major (9.2{\%}) and 14 minor (25.9{\%}). In the assessable patients, platelet response was 8/13 (61{\%}) and neutrophil response was 13/17 (76.4{\%}). Only in patients with erythroid improvement, multilineage responses were observed. Apparently, patients with greater erythropoiesis dysfunction may take more advantage.",
keywords = "Hematological improvement, Iron-chelation therapy, Myelodysplastic syndromes",
author = "Alfredo Molteni and Marta Riva and Annamaria Pellizzari and Lorenza Borin and Alessandra Freyre and Rosa Greco and Marta Ubezio and Massimo Bernardi and Alessio Fariciotti and Guido Nador and Michele Nichelatti and Emanuele Ravano and Enrica Morra",
year = "2013",
month = "10",
doi = "10.1016/j.leukres.2013.07.006",
language = "English",
volume = "37",
pages = "1233--1240",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Ltd",
number = "10",

}

TY - JOUR

T1 - Hematological improvement during iron-chelation therapy in myelodysplastic syndromes

T2 - The experience of the "Rete Ematologica Lombarda"

AU - Molteni, Alfredo

AU - Riva, Marta

AU - Pellizzari, Annamaria

AU - Borin, Lorenza

AU - Freyre, Alessandra

AU - Greco, Rosa

AU - Ubezio, Marta

AU - Bernardi, Massimo

AU - Fariciotti, Alessio

AU - Nador, Guido

AU - Nichelatti, Michele

AU - Ravano, Emanuele

AU - Morra, Enrica

PY - 2013/10

Y1 - 2013/10

N2 - To analyze the unpredicted event of hematological improvement (HI) during iron-chelation therapy (ICT), we reviewed a series of 53 myelodysplastic patients with transfusion dependency in a retrospective study involving 8 centers afferent to the "Rete Ematologica Lombarda". According to the IWG response criteria published in the year 2000, we observed erythroid responses in 19 patients (35.1%), 5 major (9.2%) and 14 minor (25.9%). In the assessable patients, platelet response was 8/13 (61%) and neutrophil response was 13/17 (76.4%). Only in patients with erythroid improvement, multilineage responses were observed. Apparently, patients with greater erythropoiesis dysfunction may take more advantage.

AB - To analyze the unpredicted event of hematological improvement (HI) during iron-chelation therapy (ICT), we reviewed a series of 53 myelodysplastic patients with transfusion dependency in a retrospective study involving 8 centers afferent to the "Rete Ematologica Lombarda". According to the IWG response criteria published in the year 2000, we observed erythroid responses in 19 patients (35.1%), 5 major (9.2%) and 14 minor (25.9%). In the assessable patients, platelet response was 8/13 (61%) and neutrophil response was 13/17 (76.4%). Only in patients with erythroid improvement, multilineage responses were observed. Apparently, patients with greater erythropoiesis dysfunction may take more advantage.

KW - Hematological improvement

KW - Iron-chelation therapy

KW - Myelodysplastic syndromes

UR - http://www.scopus.com/inward/record.url?scp=84883554593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883554593&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2013.07.006

DO - 10.1016/j.leukres.2013.07.006

M3 - Article

C2 - 23906627

AN - SCOPUS:84883554593

VL - 37

SP - 1233

EP - 1240

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 10

ER -